GFAP/D-Dimer Point-of-Care Testing & CEREBO Near-Infrared Spectroscopy (NIRS)CT Head
GFAP/D-Dimer Point-of-Care Testing & CEREBO Near-Infrared Spectroscopy (NIRS): A finger-prick blood sample will be obtained from patients with suspected acute stroke and tested using a GFAP/D-Dimer lateral flow assay. The test will provide rapid biomarker results to support differentiation between ischemic stroke and intracerebral hemorrhage in the prehospital setting and The handheld CEREBO-NIRS device will be applied non-invasively to the patient's scalp to detect intracranial hematoma by assessing asymmetry in near-infrared optical density. The findings will be recorded and used as part of the PREDICT Assessment Model for stroke subtype classification.
CT Head: Standard care CT head imaging
Study summary
CEREBO is an ICMR award winning point-of-care (POC) adjunct CT scanning device for detecting brain hematomas in patients with head injury. The study aims to validate the diagnostic accuracy of the PREDICT Assessment Model (CEREBO-NIRS plus GFAP/D-Dimer POC Assay) in patients with suspected stroke. The study will be conducted as part of the Indian Council of Medical Research's National Health Research Priority (ICMR-NHRP) under the INDIA-EMS project using a two phase design.
PHASE I: Validation of a diagnostic accuracy and feasbility of PREDICT assessment model (a combined approach using GFAP/ D-dimer POC lateral flow assay plus CEREBO-NIRS technology).
Study Design: Prospective, Multicenter, Validation and Feasibility Study.
PHASE II: Pilot RCT to assess integration of the PREDICT assessment model into pre-hospital pathways.
Study Design: Pilot Randomized Controlled Trial (RCT) (Year 3-5)
Eligibility
Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Phase 1
Inclusion criteria
* Adult patients of any gender ≥18 years with clinically suspected stroke
* Transported by ambulance or presenting directly to ED of participating hospitals
* Time from symptom onset/ Lost known well time (within 24 hours)
* Consent provided by patient/ next of kin
Exclusion criteria:
* Patients with known pre-existing neurological conditions that may confound diagnosis (Concurrent traumatic brain injury, recent TBI in last 3months, IS/ICH in last 3 months, Diagnosis of brain tumour/SOL)
* Patients with known medical condition with estimated life expectancy ≤ 3 months
* Those refusing consent
Phase 2
Inclusion criteria:
* Adult patients of any gender ≥18 years with clinically suspected stroke
* Transported by ambulance to ED of participating hospitals
* Time from symptom onset/ Last well known time (≤ 24 hours)
* NIHSS ≥ 5
* Consent provided by patient/ next of kin
Exclusion criteria:
* Patients with known pre-existing neurological conditions that may confound diagnosis (Concurrent traumatic brain injury, recent TBI in last 3months, IS/ ICH in last 3 months, Diagnosis of brain tumour/ SOL)
* Patients with known medical condition with estimated life expectancy ≤ 3 months
* Those refusing consent
Primary outcome measure(s)
PREDICT assessment model — 30 mins (Phase 1) Sensitivity and Specificity and PREDICT assessment model. Accurate identification of ICH \>90% using PREDICT model.
Time for Device Application by Paramedics — 30 mins (Phase 1) The time taken by paramedics/ ED personnel to apply the CEREBO NIRS device and obtain GFAP/D Dimer results. Lesser time indicates good outcome.
Treatment initiation — 30 mins (Phase 2) Time from Ambulance dispatch to initiation of stroke-specific treatment (Triage to Stroke ready centre or rapid BP control). Lesser time indicates better outcome.
Trial sites (2)
Facility
City
Region
Status
Jawaharlal Institute of Postgraduate Medical Education and Research Puducherry JIPMER
Puducherry
Puducherry
Christian Medical College and Hospital
Ludhiana
Punjab
More Christian Medical College and Hospital, Ludhiana, India trials in India
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.